TABLE 1.
Results from treating IRAK pathway knockout cells with the MYD88 ST2825 dimerization inhibitor
| Cell line | EC50 value (μM)a
|
SD | |||
|---|---|---|---|---|---|
| Replicate 1 | Replicate 2 | Replicate 3 | Avg | ||
| BCBL-1 WT | 4.3 | 7.1 | 8.8 | 6.7 | 2.2 |
| ΔIRAK4.1 | 9.3 | 3.3 | 4.9 | 5.8 | 3.1 |
| ΔIRAK4.2 | 4.9 | 5.4 | 18 | 9.3 | 7.3 |
| ΔIRAK1.1 | 29 | 2.3 | 5.1 | 12 | 14 |
| ΔIRAK2.2 | 16 | 2.6 | 5.4 | 8.0 | 7.0 |
| ΔMYD88.1 | 3.6 | 3.5 | 8.3 | 5.1 | 2.8 |
| ΔMYD88.2 | 3.6 | 2.6 | 7.9 | 4.7 | 2.8 |
Three biological replicates, each the average from 4 technical replicates.